Background: Tesofensine (TE) is a new drug producing twice the weight loss in obese individuals as seen with currently marketed drugs. It inhibits the presynaptic reuptake of the neurotransmitters noradrenaline, dopamine and serotonin, and is thought to enhance the neurotransmission of all three monoamines. The mechanisms by which it produces weight loss in humans are unresolved. Objective: The aim of this study is to investigate the mechanism(s) behind weight reduction by measuring energy expenditure and appetite sensations in overweight and obese individuals. Design: Thirty-two healthy, overweight or moderately obese men were treated with 2.0 mg TE daily for 7 days followed by an additional 7 days with 1.0 mg TE daily or corresponding placebo (PL) in a randomized, controlled trial. They were instructed to maintain habitual food intake and physical activity throughout. Twenty-four-hour energy expenditure (24-h EE), fat oxidation and spontaneous physical activity were measured in a respiration chamber before and after treatment. Body composition was assessed by dual-energy X-ray absorption and appetite was evaluated by visual analogue scales in conjunction with a standardized dinner. Results: Despite efforts to keep body weight and composition constant, TE induced a 1.8 kg weight loss above PL after 2 weeks' treatment (Po0.0001). TE also induced higher ratings of satiety and fullness and concomitantly lower prospective food intake than placebo. No significant effect of TE on total 24-h EE could be demonstrated compared with PL, but higher energy expenditure was observed during the night period (4.6%; Po0.05) when adjusted for changes in body composition. Furthermore, TE increased 24-h fat oxidation as compared with PL (18 g; Po0.001). Conclusion: TE has a pronounced effect on appetite sensations and a slight effect on energy expenditure at nightFboth effects can contribute to the strong weight-reducing effect of TE.
Introduction
The prevalence of obesity in industrialized countries has increased continuously over the past 30 years. 1 Data from the National Health and Nutrition Examination Survey III show that 32% of adults in the United States were obese (body mass index X30.0 kg m À2 ) in 2003-04. 2 As overweight and obesity are major risk factors for diseases such as type 2 diabetes, coronary heart disease, sleep apnoea and certain cancers, 1 extensive efforts have been made to improve their treatment and prevention. Unfortunately, with the exception of bariatric surgery, these treatments most often produce only a modest and transient weight. [3] [4] [5] As bariatric surgery is indicated only in a minority of patients (classically those with a body mass index X40.0 kg m À2 ), the vast majority of obese adults need novel treatments, in addition to behavioural modifications including dietary and exercise interventions, to help them lose weight and subsequently maintain a healthy body weight. New chemical entities targeted at the increasing obese population are being investigated for potential anti-obesity effects. They all aim, through various mechanisms of action, to safely improve weight loss and maintenance obtained through diet and exercise alone, by decreasing energy intake or uptake (for example, of fat), sometimes in combination with stimulation of thermogenesis.
Tesofensine (TE) inhibits the presynaptic reuptake of the neurotransmitters noradrenalin, dopamine and serotonin. 6 Selective serotonin reuptake inhibitors are used to treat depression and eating disorders, but they have generally failed to produce sustained weight loss. 7 Sibutramine, in addition to its effect on serotonin, also inhibits the reuptake of other monoamines and has been shown to enhance postprandial satiety, reduce total calorie intake and to diminish the decline in energy expenditure usually associated with a diet-induced negative energy balance. [8] [9] [10] A meta-analysis of four, randomized, placebo (PL)-controlled, double-blind, phase-II trials over 14 weeks in a total of 968 patients, examining the effect of TE on body weight in subjects with Parkinson's or Alzheimer's disease, showed a PL-adjusted, unintended weight loss of up to 4% in an obese subgroup treated with TE. 11 Recently published data from the first randomized, double-blind, Pl-controlled phase-II trial in primarily healthy, obese subjects showed that TE was able to produce B10% greater weight loss than PL after 24 weeks of 0.5 or 1.0 mg TE daily. 12 This is about twice that of currently approved drugs. Appetite was significantly suppressed after an overnight fast after treatment with TE in this study. However, energy balance could also have been affected by a simultaneous stimulation of thermogenesis, as has been seen in animals. 13 The aim of this study was to assess the potential effect of TE on energy metabolism and on subjective appetite sensations. It was designed as a 14-day randomized, double-blind, PL-controlled, parallel-group, single-centre study including overweight or moderately obese, healthy male subjects.
Subjects and methods
Subjects, inclusion and exclusion criteria Screening of subjects took place at the investigational site. Potential subjects were recruited by public advertisement in daily newspapers. Thirty-two male subjects were recruited after having signed an informed consent form. They were randomly assigned to one of the two treatment groups at the baseline visit.
To comply with inclusion and exclusion criteria, subjects had to have a body mass index between 28 and 35 kg m À2 , age between 18 and 50 years, not undergoing a physical training programme or planning major changes in physical activity during the study, not use tobacco, not taking any concomitant medication including high-dose vitamins or regular OTC preparations, not abuse or be dependent on any drug, including alcohol, have no endocrine, neurological or psychiatric diseases, hepatic or renal dysfunction, hypercholesterolaemia or hypertriglyceridaemia, thyroid disease, malabsorptive intestinal disorders, no weight change of 43 kg within 2 months before screening, surgically treated obesity, systemic infections, or inflammatory diseases, cardiovascular disease or significant abnormalities on the electrocardiogram, hypertension (X155 systolic and/or X95 mm Hg diastolic blood pressure), heart rate (HR) 490 beats per minute (b.p.m.), cancer within the past 5 years (excluding treated basal cell carcinoma), human immunodeficiency virus infection or serological evidence of active hepatitis B and/or C, clinically significant eye disorder or medication with known ocular toxicity, not previously been treated with TE or any other investigational drug within 30 days or five half-lives (whichever was longer) preceding the first dose of study drug.
Treatment TE has a very long half-life of about 8 days in humans and the clearance after oral administration is low (30-40 ml min
À1
). After the first chamber visit, subjects were randomly allocated to either PL or TE, 2 mg taken orally once daily for 7 days followed by 1 mg the next 7 days. The uptitration with 2 mg was chosen to obtain a steady-state level on 1 mg TE within the 2-week study period.
Study protocol
Each subject took part in the study for a total of 7-8 weeks, divided into a run-in period of 7-14 days, 14 days of treatment and a 28 (±3) days follow-up period. Subjects were informed about the importance of weight stability. They were counselled by a dietician on how to maintain dietary habits and not to change their physical activity in order to maintain energy balance and minimize changes in body weight and composition. After the experimental treatment period, subjects were invited to be included in a weight-reduction programme for 6 months, consisting of individual and group counselling sessions, aimed to help them to adopt a calorie-restricted, low-fat diet and to increase their physical activity.
After the run-in period, 24-h energy expenditure (24-h EE) and related measures were conducted in a respiratory chamber calorimeter at baseline (Day À1 to 0) and at the end of treatment (Day [13] [14] . The subjects were instructed not to perform any strenuous physical activity and to refrain from alcohol consumption during the 2 days before the chamber measurements. Moreover, for additional standardization and in order to accustom them to the chamber and thereby reduce the effect of potential mental stress during the subsequent 24-h measuring period, subjects slept in the chamber with the door open at the night before the actual measurement (Day À2 and Day 12). The measurements started at Day À1 and Day 13 at 0900 hours and ended 24 h later (that is, Day 0 and Day 14 at 0900 hours).
The respiratory gas exchange was measured in one of the department's two duplicate respiration chambers. 14, 15 The
Effect of tesofensine on energy metabolism and appetite A Sjödin et al same chamber was used on both occasions for any subject. The possible difference between the two chambers is accounted for in the statistical model. Gas exchange in the chamber was calculated from measured airflow and concentrations of O 2 and CO 2 at the outlet of the chamber as well as in the fresh air going in. Energy expenditure and substrate partitioning were later calculated based on equations by Elia and Livesey, 16 including data on nitrogen losses in urine from the same time period (analysed according to the Kjeldahl method). Subjects were instructed to be sedentary during their stay in the chamber, sitting (day) or lying (night) according to the protocol, except for two short periods of defined light physical activities in the morning and in the afternoon. The physical activity comprised 15 min of cycling at 75 W and a short period of standardized light walking (25 rounds in the chamber, corresponding to B5 min). They were further instructed to go to bed at 2200 hours, but were allowed to read until 2300 hours when the light was switched off. On the next day subjects were awakened at 0730 hours, but instructed to remain quietly in bed, apart from getting up for voiding, if needed. Registration of respiratory gas exchange between 0800 and 0900 hours was used for assessment of fasting resting metabolic rate, a proxy for basal metabolic rate (BMR).
Spontaneous physical activity (SPA) was assessed by two microwave radar detectors (Sisor Mini-Radar, Statistic Input System SA, Lausanne, Switzerland). The radar detected when the subject was moving, and the generated signal was received by the transceiver and electronically stored for later analyses. SPA measurements indicate the percentage of time when the subject was active. A laboratory technician kept the patient under surveillance during daytime and a trained medical student was in attendance during the night.
The amount of energy provided during the chamber stay was individually calculated to cover energy expenditure, based on age, gender, body composition and physical activity. 17 The total energy content in the three meals consumed at both stays was distributed with 20% at breakfast, 33% at lunch and 47% at dinner. The contribution of energy in the diet was 35% fat, 15% protein and 50% carbohydrate, resembling a typical Danish diet. Dietary calculations were made using a database from the Danish National Food Agency ('Dankost 3000', 2006). Any leftovers were recorded and actual energy intake was re-calculated. Meals and beverages were served at 0900 hoursFbreakfast, 1300 hoursFlunch, 1500 hoursFcaffeine-free coffee or tea, 1800 hoursFdinner and at 2000 hoursFcaffeine-free coffee or tea. Water was offered ad libitum during the first chamber stay and carefully recorded. The same quantities were then served to the subject at corresponding time points during their second stay. To assess body composition, dual-energy X-ray absorption (GE Lunar Prodigy Advance, GE Medical Systems, Madison, WI, USA) scanning was carried out according to a standardized procedure, with subjects in a fasting state after leaving the chamber. At this time, body weight, abdominal sagittal diameter (reclining), and hip and waist circumference (in a standing position) were also measured to the nearest 100 g and 0.5 cm, respectively.
Appetite was assessed in conjunction with the dinner meal. Visual analogue scales (VAS), 100 mm in length with words expressing the most positive and the most negative rating anchored at each end, were used to measure feelings of hunger ('how hungry do you feel?'), satiety ('how satisfied do you feel?'), fullness ('how full do you feel?') and prospective food consumption ('how much do you think you can eat?'). Nausea was assessed simultaneously, using the same technique. All questions were formulated in Danish. 18 This procedure was performed 30 min before and again immediately before dinner (pre-meal), and repeated every 30 min thereafter (post-meal) for a total of 300 min. A composite appetite score was calculated for all time points according to the formula:
At 0900 hours the registration of 24-h respiratory gas exchange was terminated and the subjects were asked to empty their bladder and allowed to leave the chamber for evaluation of body composition by dual-energy X-ray absorption. Blood pressure was then measured with subjects in a sitting position following 5 min of rest, and blood was drawn and stored for later analysis.
Blood samples for analysis of TE pharmacokinetics were collected in the morning Day 7 (±1) and Day 14 before administration of the dose, and finally at follow-up visit Day 42 ( ± 3). Concentrations of TE (NS2330) and its active metabolite (NS2360) were later analysed by Quintiles AB (Uppsala, Sweden). Additional blood samples were taken at each visit and analysed in a central laboratory (Capio Diagnostics A/S, Copenhagen, Denmark) for safety and efficacy monitoring.
HR was calculated as an average from a continuous registration throughout the 24-h chamber visit using a portable HR monitor (Nonin Avant 4000, Nonin Medical Inc, Plymouth, MN, USA).
Potential effects on mood state were assessed using the Profile of Moods States (POMS Brief) questionnaire. 19 Standard 12-lead electrocardiograms were recorded three times with half-hour intervals at baseline (Day 0), and at the end of treatment (Day 14) at 6, 6.5 and 7 h after the dose, and analysed for potential effects on PR, QT, QRS and QTc intervals that could be attributed to TE.
Additional safety measures were treatment emergent adverse events (AEs) (collected up to 28 days after the last treatment dose), ophthalmoscopy and a standard physical examination.
Sample size and statistical analyses
Under the assumption that the s.d. of a 24-h EE measurement is 150 kJ, the study was powered to detect a treatment difference of 300 kJ for the 24-h EE measurement using a Effect of tesofensine on energy metabolism and appetite A Sjödin et al two-sided test, a significance level of 5%, a power of 90% with 13 subjects in each treatment arm. Expecting B20% withdrawals, a total of 16 subjects was therefore included in each treatment arm. The basic model for the analysis of continuous end points at Day 14 was an analysis of variance with treatment as a class effect and subjects as random effects. The error variances were allowed to differ between treatment groups. Baseline values were used as covariates. Treatment differences, adjusted for covariates (for example, SPA, fat free mass) in the final model, were shown with a two-sided 95% confidence interval (CI), as well as the corresponding P-value. Analyses of the appetite profile were carried out by a repeated measures analysis of variance with treatment and time points as fixed effects and a covariance structure reflecting the dependence among observations at different time points for any subject. The covariance structure was allowed to differ between treatments.
A level of significance of 5% was used to decide statistical significance for primary and secondary end points. The tests were two sided. For the secondary end points, no correction for multiplicity was used. Two respiration chambers were used. The same chamber was used on both occasions for a specific subject, but differed between subjects. The possible difference between the two chambers was taken into account in the model. Randomization data were kept strictly confidential, accessible only to authorized persons, until the time of un-blinding.
Site, ethics and monitoring
The study was carried out at the Department of Human Nutrition, Copenhagen University, Denmark, between March and December 2007. All subjects gave written informed consent before any study-related procedures. The project was registered at http://www.ClinicalTrials.Gov 
Role of the funding source
The research relating to this paper was funded by NeuroSearch A/S (Ballerup, Denmark).
The study was designed by an external advisory board with representatives from the sponsor and with the principal investigator (AA) as chairman. Data were collected by the monitoring company (Cyncron AS) and were assessed jointly by the statisticians, the authors and the sponsor. The data were interpreted and the paper was written by the authors.
The authors had full access to all data and had joint final responsibility for the decision to submit for publication.
Results
Study population, protocol compliance and dropouts A total of 32 Caucasian subjects were successfully screened and subsequently randomized to treatment with either TE or PL. The treatment groups had similar demographic and baseline characteristics ( Table 1 ). The reported drug compliance was high with no difference seen between groups. Of a total of 21 prescribed tablets, 20.8±1.4 and 20.3±1.2 tablets were reported taken in the TE and PL groups, respectively. The short, but initially high, dosing of TE in this study produced plasma concentrations (mean±s.d.) at days 7, 14 and 42 ± 3 (follow-up) of TE of 14.95 ± 4.37, 16.20 ± 3.77, 1.72 ± 1.24 ng ml À1 and of its metabolite, N-desmethyl-metabolite NS2360 of 1.12±0.45, 2.67±0.76 and 1.11 ± 0.69 ng ml
À1
, respectively. Plasma concentrations of these compounds were below detection levels (0.01 ng ml
) in all subjects receiving PL. One subject in the PL group could not be persuaded to take part in the follow-up assessment, but this subject was still included in the efficacy analyses because complete data sets were obtained from both chamber visits. One subject in the TE group withdrew consent during the intervention because of an adverse advent (abdominal pain or suspected peptic ulcer). All the remaining subjects completed all procedures per protocol, with the exception that despite encouragement, two subjects in the TE group could not eat all the food designated for their consumption during the second time in the chambers due to extreme fullness. On average, this led to Effect of tesofensine on energy metabolism and appetite A Sjödin et al a 1% lower energy intake for the entire group (not significant). In contrast, none of the subjects receiving PL treatment had any problems eating the portions served to them.
Weight and body composition
Despite the efforts taken to minimize alterations in body weight and composition between chamber visits, TE-treated subjects lost more body weight compared with subjects in the PL group. This was due to losses of both FM and FFM. Changes in sagittal abdominal diameter as well as waist circumference and waist/hip ratio did, however, not reach statistical significance within the time of observation (Table 2) .
Energy metabolism
The 24-h EE corrected for changes in FFM was not significantly affected by TE treatment ( þ 2.2 J kg À1 min
À1
(95% CI: À1.3; 5.7) P ¼ 0.22) compared with PL. However, during the night period (2300-0800 hours; a proxy for sleeping metabolic rate), EE/FFM was higher after TE treatment ( þ 4.1 J kg À1 min À1 (95% CI: 0.1; 7.5) Po0.05) compared with PL, corresponding to an increase of 4.6% while resting metabolic rate (0800-0900 hours) was not significantly different between treatments (P ¼ 0.23) (Figure 1a )
Substrate oxidation
In the TE group, total 24-h fat oxidation increased by 17.7 g (95% CI: 1.4; 48.9) compared with PL (Po0.001) (Figure 1b) . Concomitantly, a 1.8 g (95% CI: 0.1; 3.5) lower nitrogen excretion was found (Po0.05), indicative of a lower protein oxidation while carbohydrate oxidation remained unchanged.
Appetite Subjective appetite sensations evaluated by VAS scores before the dinner (pre-meal) were higher for fullness (5 vs À5 mm;
Po0.01), satiety (20 vs À3 mm; Po0.05) and composite appetite (12 vs À4 mm; Po0.01), whereas subjects scored lower on prospective consumption (À17 vs 4 mm; Po0.01), after TE compared with PL ( Figure 2 ). PL-subtracted values for hunger did, however, not reach statistical significance (À5 vs 5 mm; P ¼ 0.17). VAS scores were also significantly different for fullness and prospective consumption throughout the entire 5-h period when appetite was assessed (Po0.05). The changes from pre-meal values in VAS scores were, however, not different for any of the appetite-related 
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A Sjödin et al questions, indicating that the response to the meal was similar for the two treatment groups. Pre-meal nausea, scoring at the low end of the scale, was slightly but significantly higher in the TE-treated group (5.6 vs 2.7 mm; Po0.05), and increased slightly, but without reaching statistical significant differences, after the test meal. Nausea did not, however, explain the effect on appetite seen after TE treatment when adjusted for in the statistical model.
SPA
The level of SPA over 24 h, measured by the radar system, was not different between groups. However, when looking separately at the night period, when subjects were mostly asleep and when a significant difference in EE was demonstrated, SPA tended to be slightly higher (0.6% units (95% CI: 0.0; 1.2) P ¼ 0.05) in TE compared with PL. An adjustment for individual differences in SPA did not, however, change the findings on EE.
HR and electrocardiogram HR increased on average by 10 b.p.m. (95% CI: 7; 12.9) throughout the 24 h of registration (Po0.0001) after TE treatment compared with PL. The difference was less pronounced during the night (2300-800 hours: 6.6 b.p.m. (95% CI: 3.6; 9.7), Po0.001) than during the day (0900-2300 hours: 12.2 b.p.m. (95% CI: 9.9; 15.4), Po0.0001). No effects on electrocardiogram apart from HR were found and there were no correlations between changes in EE and changes in HR (slightly negative slope and P ¼ 0.52 for TE-treated subjects).
Blood pressure Diastolic blood pressure increased by 4.7 mm Hg (95% CI: 1.7; 7.8, Po0.01) after TE treatment, whereas systolic blood pressure remained unchanged (1.3 mm Hg (95% CI: À2.5; 5.1), P ¼ 0.49) compared with PL.
Laboratory assessments
Compared with PL, blood lipids were reduced on TE: triglycerides by 23% (Po0.001), total cholesterol by 10% (Po0.001) and low-density lipoprotein cholesterol by 10% (Po0.01), whereas high-density lipoprotein cholesterol was unchanged (Table 3) . For free fatty acids (FFA), a significant increase was observed on TE compared with PL (by 33%, Po0.01). No significant differences were, however, observed in fasting glucose, glycosylated hemoglobin A1c (HbA1c), insulin, adiponectin, leptin, ghrelin, cholecystokinin (CCK), C-reactive protein or lactate dehydrogenase.
Profile of Moods States
Overall Profile of Moods States has not been subjected to statistical analyses due to insufficient power. However, there seems to be a tendency that subjects treated with TE reported a general slight shift in parameters in a direction associated with poorer mood compared with PL. This can be Effect of tesofensine on energy metabolism and appetite A Sjödin et al exemplified by a slight numerical increase in total mood disturbance for TE (9.8 ± 20) vs PL (1.8 ± 9.8).
AEs
No serious AEs occurred in either treatment group. The majority of the AEs were mild (42 of 57 events), whereas the number of moderate to severe AEs was higher in the TE group (seven events vs two events). A total of 39 events occurred in the TE group (in 93.8% of subjects in the group), whereas 18 events occurred in the PL group (in 62.5% of subjects in the group), with insomnia (TE 5; PL 0); headache (TE 5; PL 2), loss of appetite (TE 5; PL 3) and dry mouth (TE 3; PL 0), seemingly more frequently reported in the actively treated group. Causality showed a similar number (7 vs 7) of events deemed 'Not related' between the two treatments, whereas the number of events deemed 'Probable relation' was higher for the TE-treated group compared with controls (TE 22 vs PL 6). AE outcomes were however, similar in the two treatment groups.
Discussion
The main findings of this study, apart from the favourable effects of TE on appetite, is that treatment with TE results in decreased body weight and increased fat oxidation, although the primary outcomeF24-h EE corrected for changes in FFMFwas not significantly affected. However, it should be noted that during the night (2300-0800 hours), when subjects were generally sleeping, a significant increase in EE/FFM ( þ 4.6%; Po0.05) was observed in TE-treated compared with PL-treated subjects. Despite efforts to keep subjects' food intake and physical activity unchanged, a significant weight loss of almost 2 kg was found already after 2 weeks of treatment with TE but not with PL, complicating the interpretation of data on EE. Thermogenesis (resting metabolic rate) normally decreases during weight reduction, mainly due to loss of FFM and a reduced sympathetic nervous system activity, and to a lesser extent, due to loss of fat mass. [20] [21] [22] [23] Changes in FFM should therefore be part of an analysis when assessing a potential effect on thermogenesis. Accordingly, the loss of FFM in the TE group should theoretically have caused a decrease of 2% (Po0.05) in resting metabolic rate. 24 However, although there was a 1.9% drop in 24-h EE/FFM in the PL group (Po0.05), EE/FFM was clearly maintained in the TE-treated group ( þ 1.0%; P ¼ 0.31) (Figure 1a ). This numerical difference between groups, although not statistically significant (P ¼ 0.22), corresponds to an approximately 250 kJ increase in energy expenditure over 24 h, and could be considered a biologically meaningful effect in relation to weight regulation. It should also be acknowledged that the lack of effect of TE on the primary outcome in this trial may have been due to a statistical type II error arising from the limited sample size. Although stimulation of serotonergic and dopaminergic systems does not lead to increased thermogenesis in humans, the sympathetic nervous system driven by noradrenaline-dependent neurotransmission is a key pathway known to increase thermogenesis in man. 15, 22 It is therefore likely that the observed effect on sleeping EE is due to a higher sympathetic tone that is easier to detect during sleep, when the variability of EE is lowest. However, the effect is rather small and additional research is required to fully assess the potential effects of TE on EE. Energy expenditure can obviously be affected differently under less controlled, free-living conditions, in which subjects are not confined to a small room, instructed to be sedentary and closely monitored for adherence to the protocol. Several lines of evidence suggest that increased Effect of tesofensine on energy metabolism and appetite A Sjödin et al central monoaminergic neurotransmission affects energy expenditure, either directly by increasing thermogenesis at rest, or indirectly by increasing locomotor activity. 25, 26 An animal study showing that high doses of sibutramine increase locomotor activity has suggested that the latter might be the main mechanism by which this drug leads to increased EE 27 and subsequent weight loss. Whether this is a pharmacologically relevant mode of action of the drug when given in more moderate doses, relevant for clinical use, is however unknown. Effects on locomotion, antagonized by the dopamine D 1 -receptor antagonist SCH23390, have also been shown after administration of TE in rats. 28 It is possible that treatment with TE may also result in increased motor activity in man. However, this was not found to be the case in this study, in which an increase should have been detected as increased SPA by the radar system used in the chambers. A minor effect of potentially disturbed sleep leading to increased EE could also be suspected, as SPA tended to be slightly higher during the night after TE treatment in this study. However, EE during the night remained significantly higher in this group even after correction for changes in SPA during this period. Furthermore, there was no indication that SPA for the entire 24-h period was affected (a drop of 1.6 vs 0.9% units for TE and PL, respectively). Considering the almost equally low nanomolar efficacy on in vitro inhibition of the suggested receptors involved, 29 it is likely that TE could show a direct effect on EE through positive modulation of several monoaminergic pathways involved in metabolic activity. Animal studies with sibutramine support this assertion, as they have found a dosedependent stimulation of EE, of which brown adipose tissue metabolism accounts for the major thermogenic response. 26 Postprandial EE has also been shown to be increased when human subjects were treated with higher doses of sibutramine. 8 An effect of TE on EE was also found in a study using an inbred rat model of diet-induced obesity (DIO), in which animals treated with TE not only lost weight as a result of lowered energy intake, but interestingly also lost considerably more weight (17.9 vs 6.7%) compared with pair-fed vehicle-treated DIO animals. 13 This clearly suggests that TE, apart from its effect on appetite, also resulted in increased EE. It should be noted, however, that neither EE nor locomotor activity was assessed in this study, thus it still remains to be determined whether thermogenesis, locomotor activity, or both, contributed to this effect. TE shares the presynaptic reuptake inhibition of noradrenaline and serotonin, and potentially also of dopamine, with sibutramine. It also shows some of the same hemodynamic effects, for example, increased HR. Sibutramine has been found to exert a small thermogenic effect in humans at higher doses, 8 and it has been suggested that the thermogenic effect of sibutramine may be indirectly responsible for the increase in HR, that is, a hemodynamic effect of increased sympathetic nervous system activity and increased tissue heat production. However, in this study, we found no support for this hypothesis, as increases in HR were clearly not linked to changes in EE.
Fat oxidation was increased in the TE-treated subjects. For 24 h, this corresponded to 18 g compared with PL (Po0.05). The effect on fat utilization was also accompanied by an increased availability of FFA (elevated plasma concentration) and a reduction in serum triglyceride (s-TG) concentration. Both are likely to be effected by a period with negative energy balance per se. Although subjects during the 24-h evaluation of substrate utilization at the end of treatment were in a neutral energy balance similar to baseline conditions, a negative energy balance before this, as indicated by the weight loss seen in the TE-treated group, may have had a persistent effect on these parameters. When corrected for weight changes, the effects on s-TG, total and low-density lipoprotein cholesterol disappeared, while the enhancing effect on fat oxidation no longer reached statistical significance (P ¼ 0.13).
As could be expected based on the proposed effects of TE on a number of monoaminergic postsynaptic receptors, appetite was found to be robustly affected in this study, which is also in line with results from the previous phase-II trial in obese subject. 12, 30 The elevated feelings of fullness and satisfaction, in combination with a higher composite appetite score and a simultaneously lower anticipated food consumption at a following meal, would probably result in lower energy intake in an ad libitum meal situation, and would most likely result in a lower habitual energy intake. However, this has still to be demonstrated in future studies. It is plausible that the effect on appetite is the main mechanism leading to the negative energy balance and subsequent weight loss seen with treatment with TE. Reduced appetite may be due to nausea. The pre-meal VAS score for nausea was also slightly higher for TE compared with PL. However, both groups reported scores in the lower range and VAS scores for appetite were not affected when nausea was included as a covariate in the analysis. It should also be noted that only one subject (in the TE-treated group) reported mild nausea as an AE. The mechanisms by which TE might affect appetite are not fully understood. The multiple targets of TE inhibiting noradrenaline, serotonin and dopamine reuptake function, and thereby potentially influencing a great number of monoaminergic postsynaptic receptors, make any prediction of specific anatomical and pharmacological targets particularly difficult. However, very recent animal studies have helped us in our understanding of the receptors involved in the immediate appetite-suppressing effect of TE. 28 Acute administration of TE to diet-induced obese rats was shown to immediately suppress food intake. The hypophagic response was almost completely reversed by co-administration of prazosin (a 1 -adrenoreceptor antagonist) and partially antagonized by co-administration of SCH23390 (a dopamine D 1 -receptor antagonist). Other monoamine antagonists tested were ineffective. On the basis of these findings, it is most likely that the acute effect on appetite is mainly Effect of tesofensine on energy metabolism and appetite A Sjödin et al mediated by á 1 -adrenoceptors, presumably located in the medial hypothalamus, and perhaps by a minor contribution from dopamine D 1 -receptors, likely located in the ventral striatum. However, these observations are restricted to the acute effects of TE, and do not exclude that other targets might be involved in other aspects of the potentially multiple chronic effects of TE on metabolism and appetite, or whether the same targets may have several roles. Administration of TE to obese subjects in doses from 0.25 mg and upwards has been shown to induce a small but significant increase in HR at rest. 12 A mild increase in supine diastolic and systolic blood pressure of 1-3 mm Hg was also seen at 0.25 and 0.5 mg doses, which are the doses to be used for further clinical development. Only the highest dose of TE (1 mg) induced a significant increase in blood pressure in obese patients. These changes in vital signs were generally less pronounced in an elderly population with Parkinson's and Alzheimer's disease.
11
Although the types of AEs reported in this study were in line with those in longer-term intervention studies, 11, 12 the incidence of some AEs tended to be higher, and the effects on blood pressure and HR were more pronounced. However, this is probably explained by the forced titration scheme used in this study (2 mg per day for 7 days) in order to achieve steady state concentrations equivalent to 1 mg per day. The effects on vital signs found in this short-term study have therefore to be thoroughly evaluated under relevant clinical conditions in future trials. Several weight-reduction studies have found that the relative reduction in BMR is larger than the relative reduction in body weight. 31, 32 Other studies have indicated that a lower BMR for a given body size and composition may be involved in some cases of obesity. In a prospective study, Ravussin et al. 33 reported that subjects with a low BMR, adjusted for body composition, were at higher risk of subsequent weight gain than subjects with a high adjusted BMR. Furthermore, a meta-analysis of BMR has shown that formerly obese subjects have a 3-5% lower weight-adjusted BMR than matched never-obese controls. 34 If TE has a sufficient thermogenic effect to attenuate the decline in metabolic rate seen after weight reduction, without causing unacceptable adverse effects, this could help maximize the impact on weight of its demonstrated effect on food intake. A combination of stimulation of thermogenesis and suppression of food intake may thus have the potential to produce better long-term weight loss than energy restriction alone. Even a slight thermogenic effect of B250 kJ per day, as indicated in this study, would then allow body weight to become stabilized at a slightly higher and more acceptable level of energy intake.
Conclusion
This study found a clear effect on appetite sensation and a slightly reduced energy expenditure during the night after
